{
    "medicine_id": "015941be2c49aae890f9f228e1d3ca9f0ea06c36",
    "platform_id": "DB01057",
    "metadata": {
        "name": "Phospholine Iodide 6 25 mg 5mL Powder for solution",
        "composition": "6 25 mg 5mL Echothiophate",
        "clinical_particulars": {
            "therapeutic_indications": "For use in the treatment of subacute or chronic angle closure glaucoma after iridectomy or where surgery is refused or contraindicated",
            "contraindications": {
                "disease": "Side effects include blurred vision or change in near or distant vision and eye pain LD50 174 mcg kg in rats MSDS",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Echothiophate Iodide is a potent long acting cholinesterase inhibitor used as a miotic in the treatment of glaucoma Echothiophate iodide will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eyedrop therapy",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00975",
                        "description": "The therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole"
                    },
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Echothiophate"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Echothiophate may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Echothiophate"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Hydroxyzine"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Echothiophate"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}